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ABSTRACT 
Objective: The objective of the present investigation was to design and characterize a mucoadhesive buccal patch of Nebivolol hydrochloride in 
order to administer a small dose of a drug to treat hypertension effectively and thereby avoiding disadvantages such as patient noncompliance and 
low bioavailability. 
Methods: The buccal patches were prepared by solvent casting method. The polymers used to formulate patches were HPMC K 15 M, PVP K 30, and 
propylene glycol was used as plasticizer and ethanol as the solvent. The drug-polymer compatibility studied was conducted by FTIR. 
Results: All the developed Patches had good transparency and stability. All formulated patches showed pH in the range of 6.49 to 7.22, and drug 
content was more than 90%. The folding endurance value showed that the patches are flexible and non-brittle. The in vitro residence time was 
found to more than 30 min. Thickness, % moisture absorption, and % moisture loss values were in a normal range. The drug release study was 
conducted for 8 h, and it was found drug release was decreased with the increase in polymer concentration. The in vitro release profiles of the drug 
from all the formulations appeared to follow Korsmeyer Peppa's exponential model, and release exponent (n) was found to be more than 0.45 so 
that the release can be characterized by Non–Fickian (anomalous) diffusion.  
Conclusion: From the results, it was concluded that drug released from formulated buccal patches follows sustained release pattern, Hence can be 
used for the treatment of the hypertensive patient.  
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INTRODUCTION 
Hypertension (HTN) or high blood pressure, sometimes called arterial 
hypertension, is a chronic medical condition in which the arteries' 
blood pressure is elevated. High blood pressure is present if it is often 
at or above 140/90 mm Hg. Hypertension is classified as either 
primary (essential) hypertension or secondary hypertension [1, 2]. 
The oral route is the most popular and convenient drug administration 
route. However, oral administration cannot achieve the maximum 
bioavailability of many drugs because of rapid or extrahepatic first-
pass metabolism [3]. Among the different approaches to avoiding the 
first-pass metabolism, the buccal route seems convenient [4]. 
Buccal administration refers to a route of administration or topical 
route of administration. Drugs held or applied in the buccal area (in 
the cheek) diffuse through the oral mucosa (tissues that line the 
mouth) and enter directly into the bloodstream. Buccal 
administration may provide better bioavailability of some drugs and 
more rapid onset of action than oral administration. The medication 
does not pass through the digestive system and thereby avoids the 
first-pass metabolism. Various mucoadhesive devices, including 
tablets, films, patches, disks, strips, ointments, and gels, have 
recently been developed. However, buccal patches offer greater 
flexibility and comfort than other devices. Besides, a patch can 
circumvent the relatively short residence time of oral gels on 
mucosa since the gels are easily washed away by saliva. Other 
advantages such as excellent accessibility, low enzymatic activity, 
suitability for drugs or excipients that mildly and reversibly damage 
or irritate the mucosa, painless administration, easy withdrawal, 
facility to include permeation enhancer/enzyme inhibitor or pH 
modifier in the formulation, versatility in designing as 
multidirectional or unidirectional release system for local or 
systemic action. There are mainly 3 methods to prepare 
mucoadhesive buccal patch; they are solvent casting technique, hot-
melt extrusion technique, and solvent evaporation method [5]. 
Polymers frequently used in the buccal delivery system are CMC, 
HEC, HPC, HPMC, MC, Chitosan, etc. 
Nebivolol Hydrochloride (NBH) is a drug with low water solubility and 
high membrane permeability, as in class 2 in the Biopharmaceutical 
Drug Classification System. NBH is a beta-blocker that exerts its 
actions by exhibiting a high selectivity for B-adrenergic receptors and 
reducing peripheral vascular resistance by modulating nitric oxide 
release [6]. Nebivolol is indicated as medicine for Essential 
Hypertension but, it has some drawbacks like extensive first-pass 
metabolism, gastric irritancy, and low bioavailability. Further, the low 
aqueous solubility and poor dissolution of this molecule in gastric fluid 
affect its absorption rate, resulting in a low and variable oral 
bioavailability. Formulation of poorly water-soluble drugs as solid 
dispersions leads to increased solubility and decreased 
gastrointestinal side effects. The resulted of that marked improvement 
in their dissolution rates and decreased gastrointestinal side effects. 
An increase often helps it in their relative bioavailability [7, 8]. So, to 
improve the solubility, bioavailability and avoid hepatic metabolism, in 
the present study, an attempt was made to develop solid dispersion 
loaded buccal patches of Nebivolol [9, 10]. NBH also has a low 
molecular weight and high partition coefficient, making it a suitable 
candidate for the buccal delivery system. 
MATERIALS AND METHODS 
Materials 
Nebivolol Hydrocholride was a gift sample Cipla Pharma Ltd. (Banglore, 
India). Hydroxy propylmethyl cellulose (K15 M) was obtained from 
Yarrow chem products. (Mumbai, India) and Polyvinyl pyrolidone K 30 
(PVP K30) was obtained from Central drug house (P) Ltd. (Delhi, India). 
Ethanol was obtained from Merck specialities Private Limited, (Mumbai, 
India). Propylene glycol 800 was obtained from Sisco laboratories 
(Mumbai, India). All other chemicals used were of analytical grade and 
procured from Hi media laboratories (Mumbai, India). 
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Fabrication of nebivolol solid dispersion infused buccal patch 
The buccal patches containing Nebivolol solid dispersions were 
prepared by incorporating solid dispersions of Nebivolol in a 
different composition of Hydroxypropyl methylcellulose (HPMC) 
K15 M polymer. Solid dispersions of Nebivolol were prepared as by 
Shah I et al., in that 1:7 ratio of drug and PVP K 30 was taken. 
Different percentages of HPMC K 15 M were taken and dissolved in 
20 ml of ethanol. The beakers containing polymer solution were 
kept aside for 24 h for swelling of the polymer. Further, 5 ml of 
ethanol was added to it, and the dispersion was stirred. Then 
propylene glycol was added to the polymer solution and mixed well.  
Accurately weighed amounts of Nebivolol loaded solid dispersion 
were taken, added slowly in the polymeric solution, and stirred on 
the magnetic stirrer to obtain a uniform solution. This solution was 
then made up into 30 ml using ethanol, and then the solution was 
poured on the Petri dish of diameter 9 cm and kept for drying. These 
were left undisturbed at room temperature for one day. After drying, 
medicated patches of 2×2 cm2 areas were cut using a sterile 
stainless steel borer, each film containing 10.0 mg of the drug. The 
cut patches were used for further studies [6, 11]. The composition of 
different formulation showed in table 1. 
Drug excipient compatibility studies 
To determine whether there are any interactions between the drug 
and excipients, FTIR spectroscopic analysis was performed using the 
instrument BRUKER Alpha II in the region of 2000 to 400 cm-1. All 
individual components of drug, drug-polymer mixture and patch 
were analysed. 
 




Solid dispersion equivalents to 
10 mg of nebivolol 









F1 80 20 30 0.25 0.02 Q. S. 
F2 80 25 30 0.25 0.02 Q. S. 
F3 80 30 30 0.25 0.02 Q. S. 
F4 80 35 30 0.25 0.02 Q. S. 
F5 80 25 20 0.25 0.02 Q. S. 
F6 80 25 40 0.25 0.02 Q. S. 
 
Characterization of buccal mucoadhesive patches 
Weight variation  
A weight variation test was carried out using digital balance (Mettler 
Toledo), by weighing three films containing a specific amount of 
drug from each formulation. The standard deviations (SD) were 
calculated from the individual weight of the film [11-13]. 
Film thickness 
The thickness of the films was determined using a micrometer screw 
gauge. Thickness of 10 films of each formulation was determined 
and the average was calculated.  
Content uniformity of patches 
To make sure uniform distribution of NBH in film, a content 
uniformity test was performed. The film was added to 100 ml of 
sorensons phosphate buffer (SPB) pH 6.4 contained in a 250 ml 
beaker was placed on a temperature controlled magnetic stirrer 
maintained at 37 °C. The medium was stirred at 300 rpm with a 
Teflon coated magnetic bead for 3 h. Then the solution was 
filtered through 0.45 µm membrane filter and the filtrate was 
examined for the drug content at 281 nm using UV-
Spectrophotometer [13].  
Surface pH study  
The surface pH of the patch was determined in order to investigate 
the possibility of any side effects (in vivo). The patches were allowed 
to swell by keeping it in contact with 1 ml of distilled water (pH 
6.5±0.2) for 15 min at room temperature, and pH was noted down 
by bringing the electrode in contact with the surface of the patch and 
allowing it to equilibrate for 1 minute [11, 13]. 
Percentage moisture absorption  
The percentage moisture absorption test was carried out to ensure 
physical stability or integrity of buccal films. Buccal films were 
weighed and placed in a desiccator containing 100 ml of a saturated 
solution of aluminum chloride and 75±5% RH was maintained. After 
three days the buccal films were taken out and reweighed. The 
percentage moisture absorption was calculated using this formula 
[14].  
 
Percentage moisture loss  
To evaluate the integrity of the patches in dry conditions percentage 
moisture loss test was carried out. The patches were weighed and 
kept in a desiccator containing anhydrous calcium chloride. After 
three days, the patches were taken out and reweighed. The formula 
used to find out the percentage moisture loss is;  
 
Tensile strength 
Tensile strength was measured using tensile analogy tester (model 
TKG, FSA, India). Films free from air bubbles or physical 
imperfections were selected for tensile testing. The two clamps of 
the tensile tester were adjusted such that the distance between them 
is 3 cm by moving the upper clamp. During measurement, the strips 
were pulled by top clamp at a rate of 100 mm/min; the force applied 
was measured until the film was broken. The film samples, which 
broke at the point of clamping and not between the clamps, were not 
included in the calculation. Triplicate results for each film were 
considered. Tensile strength can be computed from the applied load 
at rupture as a mean of three measurements and cross-sectional 
area of fractured film using the following equation [15]. 
 
Folding endurance 
A small strip of film was cut evenly and separately folded at the same 
place until it broke. The number of times the film could be folded at the 
same place without breaking gives the folding endurance [16]. 
In vitro residence time 
The in vitro residence time was determined using a locally modified 
USP disintegration apparatus (Disintegration tester, Electrolab, 
Mumbai, India). The disintegration medium was composed of 900 
ml of phosphate buffer pH 6.4 maintained at temperature 37±2 °C. A 
segment of pig buccal mucosa, 3 cm long, was glued to the surface of 
a glass slab, vertically attached to the apparatus. The mucoadhesive 
film with backing membrane was hydrated from film surface using 
15 µl phosphate buffer pH 6.4 and then the hydrated surface was 
brought into contact with the mucosal membrane. The glass slab 
was vertically fixed to the apparatus and allowed to move up and 
Priya et al. 
Int J App Pharm, Vol 13, Issue 3, 2021, 145-149 
147 
down so that the film was completely immersed in the buffer 
solution at the lowest point and was out at the highest point. The 
time necessary for complete erosion or detachment of the film from 
the mucosal surface was recorded (mean of triplicate 
determinations) [11]. 
Drug release study of the buccal patch 
In vitro release study 
The drug release studies were performed with USP dissolution test 
apparatus (Paddle method). The USP dissolution apparatus was 
thermo stated at the temperature of 37±1° C and stirred at rate of 50 
rpm. Each film was fixed on a glass slide with the help of 
cyanoacrylate adhesive so that the drug could be release only from 
upper face. Then the slide has immersed in the vessel containing 500 
ml of PB pH 6.8 phosphate buffer solution. At predetermined time 
intervals 3 ml of samples was withdrawn and replaced with fresh 
medium. After appropriate dilutions with simulated saliva was 
assayed spectrophotometrically at 281 nm. For drug release three 
films of each formulation were subjected and the average 
cumulative percentage drug release was determined [15]. 
Drug release kinetics  
To study drug release kinetics of buccal patches formulation, data 
obtained from in vitro release studies were plotted in various kinetic 
models: zero order (see Equation: 1) as cumulative percentage of 
drug released versus time, first order (see Equation: 2) as log 
cumulative percentage of drug remaining versus time [17]. 
Zero-order equation Qt
First order equation InQ




t is the percentage of drug release at time t, K0 and Kt
Mechanism of drug release  
 are 
the coefficients of the equation. 
Mechanism of drug release from vocal patches was evaluated by 
subjecting the data obtained from in vitro drug diffusion studies in 
Higuchi’s model (see Equation: 3) as cumulative percentage of drug 
released versus the square root of time and Korsmeyer–Peppa’s model 
(see equation: 4) as log cumulative percentage drug released versus log 
time [17].  
Higuchi equation Qt = Kt1/2






RESULTS AND DISCUSSION 
 is constantly incorporating structural and geometrical 
characteristics of the release device and n is the release exponent 
indicate the release mechanism. 
Buccal patches loaded with Nebovolol solid dispersion were 
prepared by solvent casting method. The prepared buccal patches 
were transparent, smooth, uniform and flexible as shown in fig. 1, 
except F6, which was tackier and non-uniform. 
 
 
Fig. 1: Buccal patch of nebivolol solid dispersion 
 
IR spectroscopy 
The major IR peaks (wave number, cm-1
 
) of pure drug and optimized 
formulation F3 are given below; Pure NBH: 3397.75, 3187.33, 
2903.02, 2845.37, 1749.30,1491.9, 1213.14, 1074.73; Optimized 
Formulation F3: 3312.97, 3188.78, 2923.41, 2735.69, 1740.33, 
1488.83, 1209.09, 1069.62. The result showed that the principle IR 
peak of pure drug and an optimized formulation F3 were almost 
similar, signifying no interaction between drug and polymer during 
formation of patch [18]. 
Table 2: Weight variation, thickness, surface pH and % drug content of developed buccal mucoadhesive patch 
Formulation Weight variation(mg)±SD Thickness (µm)±SD Surface pH±SD Drug content (%)±SD 
F1 86.63±0.28 67±0.94 7.13±0.09 95.17±0.96 
F2 104.51±0.19 89±0.81 6.87±0.09 92.20±0.76 
F3 109.05±0.36 97±0.95 6.64±0.06 94.09±1.21 
F4 114.71±0.32 107±1.63 6.51±0.11 90.88±1.09 
F5 101.63±0.21 84±1.24 6.49±0.08 91.02±0.99 
F6 103.21±0.24 88±0.47 7.22±0.06 88.45±1.22 
mean±SD (n=3) 
 
Weight variation, film thickness, surface pH, and content 
uniformity of patches 
The results of weight variation, film thickness, surface pH and 
content uniformity are represented in table 2. The weights and 
thickness of different formulations were ranged between 8.63±0.28 
mg to 114.71±0.32 mg and 67±0.94 µm to 107±1.3 µm, because of 
different concentration of polymer and plasticizer. As an acidic or 
alkaline pH may cause irritation to the buccal mucosa, an attempt 
was made to keep the surface pH as close to neutral as possible. The 
surface pH of formulations was found to be in the range of 6.49±0.08 
to 7.22±0.06, which was well within range of neutral pH and has not 
cause irritation and ultimately achieves patient compliance. All the 
formulations exhibited fairly uniform drug content ranging from 
88.45±1.22 % to 95.17±0.96 %, Formulation procedures involving 
fewer processing steps, no major drug loss was observed during the 
preparation of the films. 
Percentage moisture loss and moisture absorption 
The percentage moisture loss was found to be between 3.48±0.23 to 
6.63±0.33 and percentage moisture absorption was found to be 3.9±0.10 
to 5.71±0.33, as shown in table 3. The result revealed that the moisture 
absorption and loss was found to increase with increasing concentration 
of hydrophilic polymers as well as increase the concentration of 
hydrophilic plasticizer. The optimum moisture content in the 
formulations helps the film to remain stable, non-brittle and free from 
completely drying. Optimum values of moisture absorption in F3 
formulation indicate less chance of microbial contamination and 
maintain integrity through the films shelf life [19, 20].  
Tensile strength, folding endurance and in vitro residence time 
Tensile strength is defined as the maximum stress applied at a point 
at which the film specimen breaks. The tensile strength measures 
the ability of a patch to withstand rupture. As the concentration of 
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hydrophilic polymer HPMC K 15 M was increased, there is increase 
in tensile strength, as shown in table 3.4. Polymers contain large 
number of chain of molecules and between these chains, homopolar 
bond and other types of bonds are possible. These bonds are either 
strong or feeble, depending on the nature of the polymer. According 
to the bonds formed force required to break the bonds and rupture 
the patch will differ. The mean value of tensile strength of patch 
containing different concentrations of HPMC K 15 M was found to 
vary between 4.11±1.51to 8.55±0.98 kg/mm2 (F1 to F4). As the 
concentration of plasticizer propylene glycol was increased (20 to 
40 %) there is an increase in tensile strength (Patel and Poddar 
2009, as shown in formulation F4, F3 and F5. The mean value of 
tensile strength of patch containing different concentration of 
plasticizer was found to be 4.33±1.27, 7.72±0.40 and 8.28±0.65 
kg/mm2
 
 for formulation F4, F3 and F6, respectively. Presence of a 
plasticizer in the formulation helps in imparting strength to the films 
by lubrication effect of the plasticizer and reduction of the cohesive 
force between chain molecules of polymer. As a result, tensile 
strength of the films will be reduced. The formulation F3 showed 
optimum tensile strength which indicates less probability of rupture. 
The values for folding endurance varied from 32±3.87 to158±4.37, 
as shown in [table 3]. The value depends on hydrophilic polymer as 
well as plasticizer concentrations used. Folding endurance test 
results indicated that the patches would not break and would 
maintain their integrity with general skin folding when applied. In 
vitro residence time studies showed that all patches adhered 
immediately to the buccal mucosa and showed residence times 
above 30 min. HPMC K 15 M is a non-ionic polymer having unique 
gelling characteristics, which in turn are responsible for its adhesive 
properties. It exhibits strong bioadhesive behavior either because of 
hydrogen bonding due to hydroxyl groups or because of significant 
chain penetration or both (Thakur and Ratnaparkhi, 2014). 
Table 3: Tensile strength, folding endurance, % moisture absorption and Moisture loss of developed formulations of betamethasone 
sodium phosphate 








In vitro residence 
time ±SD 
F1 3.90±0.19 3.48±0.23 32±3.87 4.11±1.51 >30 
F2 4.09±0.32 5.73±0.39 59±2.83 5.34±0.95 >30 
F3 5.50±0.21 5.81±0.50 93±3.58 7.72±0.40 >30 
F4 5.71±0.33 6.63±0.33 158±4.37 8.55±0.98 >30 
F5 4.45±0.53 4.20±0.31 76±2.01 4.33±1.27 >30 
F6 5.23±0.43 5.33±0.42 135±4.02 5.28±0.65 >30 
mean±SD (n=3) 
 
In vitro drug release studies 
In vitro release of all formulation were performed and results are 
shown in fig. 2 and 3. The maximum percentage of drug released 
from the formulations F1 to F4 was found to be 95.88±3.03, 
92.29±2.72, 90.18±2.59, and 75.88±2.43 at the end of 480 min. It 
was found that increase in the concentration of polymer significantly 
decreased the drug release. The slow drug release mechanism for 
higher polymer concentration can be explained by the reduction in 
permeability due to change in the morphology of the polymer. 
Improved polymer concentration may have providing the matrix 
with greater tortuosity and deprived water porosity for diffusion of 
drug [20,21]. In vitro release of drug also depends on nature of 
plasticizer. As the concentration of hydrophilic plasticizer was 
increased, the release of drug was also found to be increased, 
asshown in fig. 2. It may be due to quick absorption of water by 
formation of large number of hydrogen bonds and helped in faster 
diffusion of drug from the system. Formulation F5, F3 and F6 were 
contained different concentrations of plasticizer i.e. 20, 30 and 40 % 
respectively and maximum drug release at the end of 480 min was 
found to be 62.15±2.39, 90.18±2.59 and 93.18±1.19 respectively. 
 
 
Fig. 2: In vitro release studies of buccal patches of nebivolol 
contains a different concentration of HPMC K15 M[mean±SD (n=3)] 
 
Drug release kinetics 
For the investigation of drug release kinetics, release data were fitted 
to various kinetic models and results shown in table 4. In vitro drug 
release was best fitted to zero order as the plot indicates highest 
linearity regression coefficient (R2
 
) when compared to first-order 
kinetic model. The mechanism of drug release from buccal patches 
was studied by fitting the data into Higuchi model and korsmeyer 
peppa’s exponential model. The corresponding in vitro release plot of 
Korsmeyer–peppa’s equation indicated good linearity of regression 
coefficients (Patel and Poddar 2009). Release exponent (n) was found 
to be more above 0.45, so that the release can be characterized by 
non–fickian (anomalous) diffusion, which may indicate that the drug 
release rate is controlled by more than one mechanism i.e. Diffusion 
coupled with erosion mechanism [22, 23]. 
 
Fig. 3: In vitro release studies of buccal patches of nebivolol 
contains different concentration of propylene glycol [mean±SD 
(n=3)] 
 
Based on physicochemical properties, in vitro residence time and in 
vitro drug release studies, formulation F3 was found to be 
optimized. Tensile strength of formulation F3 was sufficient to 
maintain the integrity of the film and it showed adequate residence 
time to keep the film at the site of administration. From in vitro drug 
release study, it was found that F3 showed maximum release 
(90.18±2.59) at the end of 30 min which was the prerequisite for the 
achievement of therapeutic action. However, formulations F1 and F2 
containing lower concentration of HPMC K 15 M showed more 
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release compared to F3 at the end of 480 min, but tensile strength 
was lesser than F3. But formulations F4 containing high 
concentration of HPMC K 15 M showed less release and high tensile 
strength compare to F3. Formulation F6 also showed more drug 
release compared to F3, since it content higher amount of 
plasticizer, but it was rejected because of its sticky nature. 
 
Table 4: Kinetic parameter for in vitro drug release from buccal patches of nebivolol 
Kinetic model F1 F2 F3 F4 F5 F6 
Zero Order R² 0.9701 0.987 0.9917 0.9932 0.9939 0.9683 
K -0.161 -0.162 -0.167 -0.145 -0.13 -0.14 
First Order R² 0.941 0.9495 0.9444 0.9806 0.9826 0.955 
K -0.0027 -0.0021 -0.002 -0.0012 -0.0011 -0.0022 
Higuchi R² 0.9886 0.986 0.9806 0.9885 0.9862 0.9917 
K 4.488 4.45 4.5654 3.9959 3.5718 3.924 
Korsmeyer Peppas 
model 
R² 0.9911 0.9889 0.9831 0.9972 0.9966 0.9938 
K 0.5059 0.5434 0.6208 0.7361 0.6341 0.4238 
n 0.6267 0.49 0.2688 0.102 0.1362 0.8256 
 
CONCLUSION 
The buccal patches are very comfortable due to nonirritating to tissue 
and can be easly apply and revome. The buccal patches of Nebivolol 
required lower doage compared to conventional tablets and able to 
deliver a drug over 6 hr continuously. Results illustrate the drug 
release was decreases with polymer and increases plastsizer.  
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